How much is the cholangiocarcinoma market worth, and how is it expected to expand?
The cholangiocarcinoma market size has grown rapidly in recent years. It will grow from $0.55 billion in 2024 to $0.63 billion in 2025 at a compound annual growth rate (CAGR) of 13.4%. The growth in the historic period can be attributed to the increasing incidence of liver and bile duct cancers, rising awareness about rare cancers, a growing focus on personalized treatment, a rise in immunotherapy approaches, and a rising geriatric population.
The cholangiocarcinoma market size is expected to see rapid growth in the next few years. It will grow to $1.02 billion in 2029 at a compound annual growth rate (CAGR) of 13.1%. The growth in the forecast period can be attributed to the growing adoption of precision medicine, rising healthcare expenditure, increasing prevalence of genetic testing, and growing popularity of retail pharmacies. Major trends in the forecast period include advancements in diagnostic techniques, expansion of clinical trials, integration of AI in diagnostics, advancements in drug delivery systems, expanding clinical trials, and drug development.
Get Your Free Sample of The Global Cholangiocarcinoma Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21139&type=smp
Which industry factors have accelerated the cholangiocarcinoma market’s expansion?
The increasing liver disease incidence is expected to propel the growth of the cholangiocarcinoma market going forward. Liver disease refers to any condition that impairs the normal function or structure of the liver, including diseases such as hepatitis, cirrhosis, fatty liver disease, and liver cancer. Liver disease incidence is rising due to increasing risk factors like obesity, diabetes, alcohol consumption, and viral hepatitis infections. Liver disease, particularly chronic inflammation and cirrhosis, increases the risk of cholangiocarcinoma by promoting bile duct damage and malignant cell transformation. For instance, in December 2024, according to the Office for Health Improvement and Disparities, a UK-based government agency, in 2023, premature deaths from alcoholic liver disease rose 3.6% to 5,984, up from 5,776 in 2022. Therefore, increasing liver disease incidence is driving growth in the cholangiocarcinoma market.
What are the primary segments of the cholangiocarcinoma market?
The cholangiocarcinoma market covered in this report is segmented –
1) By Cancer: Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma
2) By Product: Capecitabine, 5-Fluorouracil, Oxaliplatin, Gemcitabine, Cisplatin
3) By Therapy: Targeted Drug Therapy, Chemotherapy, Immunotherapy
4) By Route Of Administration: Oral, Subcutaneous, Intravenous
5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, E-Commerce
Subsegments:
1) By Intrahepatic Cholangiocarcinoma: Peripheral Intrahepatic Cholangiocarcinoma, Mass-Forming Intrahepatic Cholangiocarcinoma
2) By Extrahepatic Cholangiocarcinoma: Perihilar Cholangiocarcinoma, Distal Cholangiocarcinoma
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/cholangiocarcinoma-global-market-report
Which firms are leading the cholangiocarcinoma market?
Major companies operating in the cholangiocarcinoma market are F. Hoffmann-La Roche Ltd, Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Boston Scientific Corporation, Servier Laboratories, Incyte Corporation, Exelixis Inc., Hutchison China MediTech Limited, Zymeworks Inc., Agios Pharmaceuticals Inc., RenovoRx Inc., Specialised Therapeutics Pty Ltd, Ascletis Pharma Inc., Tiziana Life Sciences Ltd., Taiho Pharmaceutical Co. Ltd.
Which market trends are set to define the future of the cholangiocarcinoma market?
Major companies operating in the cholangiocarcinoma market are focusing on developing novel treatments, such as targeted therapies, to improve treatment outcomes for patients. Targeted therapies are treatments designed to focus on specific genes, proteins, or molecules that help cancer cells grow. These therapies work by blocking the processes that allow cancer to grow, aiming to stop tumor growth, reduce side effects, and improve treatment results. For instance, in August 2023, Taiho Pharmaceutical Co. Ltd., a Japan-based pharmaceutical company, launched LYTGOBI (futibatinib), an FGFR inhibitor, for the treatment of unresectable biliary tract cancer with FGFR2 gene fusions. It is designed to selectively and irreversibly inhibit FGFR signaling, helping to slow tumor growth and improve outcomes in patients with cholangiocarcinoma (iCCA) that has progressed after chemotherapy.
Which geographic trends are shaping the cholangiocarcinoma market, and which region has the highest market share?
North America was the largest region in the cholangiocarcinoma market in 2024. The regions covered in the cholangiocarcinoma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Cholangiocarcinoma Market Report 2025 Offer?
The cholangiocarcinoma market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Cholangiocarcinoma is a malignant tumor that arises from the bile ducts, which carry bile from the liver to the small intestine. It is characterized by uncontrolled growth of abnormal cells, leading to bile duct obstruction and liver dysfunction. Symptoms often include jaundice, abdominal pain, weight loss, and fatigue. Early diagnosis and treatment are crucial for better prognosis and management.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21139
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
